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a7 nAChRVarenicline is one of the most widely used drugs for smoking cessation. However, whether an adverse
effect of varenicline is associated with the risk of serious cardiovascular events remains controversial.
In this study, we determined if varenicline increases the risk of cardiovascular events using apolipopro-
tein E knockout (ApoE KO) mice. ApoE KO mice (8 weeks old) were injected with varenicline 0.5 mg kg1
day1 for 3 weeks. Varenicline aggravated atherosclerotic plaque formation in whole aorta from ApoE KO
mice compared with vehicle. Methyllycaconitine, an a7 nicotinic acetylcholine receptor (nAChR) antag-
onist, inhibited varenicline-induced aggravated plaque formation. Our ﬁndings show that varenicline
progresses atherosclerotic plaque formation through a7 nAChR, and thereby increases the risk of cardio-
vascular events.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction sial. To determine if varenicline treatment is associated with car-Smoking is an important causative and/or risk factor for the
induction and development of cardiovascular disease, ischemic
heart disease, chronic obstructive pulmonary disease, and cancer
[1,2]. Among tobacco users, cardiovascular disease occurs with
high morbidity, and is a leading cause of death. Smoking cessation
is well known to produce long-term cardiovascular beneﬁts and is
strongly recommended for patients with various diseases [3].
Varenicline has recently been introduced as an aid to smoking
cessation. It is a partial agonist of a4b2 nicotinic acetylcholine
receptors (nAChRs), and a full agonist of a7 nAChR [4,5]. Vareni-
cline is more effective than nicotine replacement therapy and
frequently used clinically for smoking cessation [6–8]. However,
varenicline shows adverse effects, most commonly headache, nau-
sea, abnormal dreams, and insomnia [9,10]. In addition to these
central adverse reactions, increased risk of cardiovascular events
has been observed in patients taking varenicline [10,11], although
there are also reports showing no signiﬁcant increase in severe
cardiovascular adverse events [12–14]. Thus, involvement of
varenicline and increased cardiovascular risk remains controver-diovascular events, we examined the effect of long-term
varenicline treatment on atherosclerotic plaque formation in apo-
lipoprotein E knockout (ApoE KO) mice.
2. Materials and methods
C57BL/6J ApoE KO mice were purchased from The Jackson Lab-
oratory (Bar Harbor, ME, USA) and housed under standard condi-
tions for humidity, room temperature, and dark-light cycles. Mice
were given free access to food and water throughout the study.
The study protocol was approved by the Laboratory Animal Care
and Use Committee of Fukuoka University.
2.1. Drugs
Varenicline tartrate was purchased from Toronto Research
Chemicals Inc. (Toronto, ON, Canada) and dissolved in saline
(Otsuka Pharmaceutical Co., Tokyo, Japan).
2.2. Experiment 1
ApoE KOmice (8 weeks old) were fed a high-fat diet (1.25% cho-
lesterol, 15% cacao butter, and 0.5% sodium cholate, F2HFD1;
Oriental Yeast Co., Tokyo, Japan). Mice were randomized into
varenicline-treated and non-treated groups, and subcutaneously
injected with either saline (vehicle, n = 8) or 0.05/0.5 mg kg1
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ing from 8 weeks old. At 11 weeks of age, mice were killed and per-
fused with ice-cold phosphate-buffered saline. The heart and aorta
were excised and analyzed histologically.2.3. Experiment 2
ApoE KO mice (8 weeks old) were fed a high-fat diet, and ran-
domized into the following three groups: (1) vehicle group treated
with saline (n = 10), (2) varenicline group treated with
0.5 mg kg1 day1 varenicline (n = 10), and (3) methyllycaconitine
(MLA) plus varenicline group injected with 5 mg kg1 day1 MLA
(an a7 nAChR antagonist) into the abdominal cavity and
0.5 mg kg1 day1 varenicline (n = 9) for 3 weeks. At 11 weeks of
age, mice were euthanized and the en face plaque area examined.2.4. En-face plaque area
To quantify the extent of atherosclerotic lesions, immediately
after mice were killed, the whole aortic length was excised forve
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Fig. 1. Atherosclerotic plaques in the aorta of varenicline-treated ApoE KO mice. (A)
Representative en face photographs of the aorta showing oil red O-stained
atherosclerotic plaques. Quantitative measurement of en face plaque area (%) in
the aortic arch (B) and whole aorta (C). Each bar indicates mean ± S.D. ⁄P < 0.05 vs
vehicle group, dP < 0.05 vs 0.05 mg kg1 day1 varenicline treatment group.quantiﬁcation of the en face plaque area, as previously described
[15–17]. Brieﬂy, after carefully removing fat and adventitial tissue,
the aortic arch and thoracic to abdominal aorta were opened lon-
gitudinally, pinned on a black wax surface, and stained with oil
red O (Sigma, St. Louis, MO, USA). En face images were obtained
using a stereomicroscope and analyzed with the public domain
software, Image J (NIH Image, Bethesda, MD, USA). Percentage of
the luminal surface plaque area stained by oil red O was
determined.2.5. Histological analysis and oil red O staining
Lipid accumulation in atherosclerotic plaques at the aortic root
in the heart was analyzed. The aortic root was embedded in O.C.T.
Compound (Sakura FineTech, Tokyo, Japan). Serial cryostat sections
(6 lm thick) were prepared as described previously [15–17].
Brieﬂy, atherosclerotic plaques were investigated in ﬁve separate
sets of sections, with each set separated by 60 lm. Oil red O stain-
ing was performed to examine lipids. The oil red O-positive area, a
marker of lipid accumulation, was analyzed using Image J. Average
values for the ﬁve sections in each animal were used for analysis.ve
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Fig. 2. Atherosclerotic plaques in the aorta of varenicline- and varenicline plus
MLA-treated ApoE KO mice. (A) Representative en face photographs of the aorta
showing oil red O-stained atherosclerotic plaques from vehicle, varenicline, and
varenicline + MLA-treated ApoE KO mice. Pooled data showing the effect of
varenicline and MLA treatment on oil red O-stained positive areas in the aortic
arch (B) and whole aorta (C). Each bar indicates mean ± S.D. ⁄⁄P < 0.01 vs vehicle
group, ddP < 0.01 vs varenicline treatment group.
Table 1
There are no signiﬁcant differences in body weight or total cholesterol between
groups. Data are expressed as mean ± S.D. N = 10 (vehicle), 10 (varenicline), and 9
(MLA plus varenicline).
Vehicle Varenicline MLA + varenicline
Body Weight, g 18.4 ± 2.6 18.4 ± 1.9 18.7 ± 2.6
Total Cholesterol, mg/dl 1952 ± 306 1920 ± 374 1997 ± 454
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At 11 weeks of age, blood was collected to measure plasma total
cholesterol levels. Plasma total cholesterol levels were measured
using WAKO Cholesterol E Assay kit (Wako Chemical Co., Osaka,
Japan).
2.7. Statistical analysis
Histological quantitative analyses were performed by a single
observer blinded to the experimental protocol. Data are expressed
as mean ± standard deviation. Bonferroni analysis was used for
comparison between the three groups. P values <0.05 were consid-
ered statistically signiﬁcant.
3. Results
3.1. Experiment 1
We determined if varenicline causes progression of plaque for-
mation in ApoE KO mice. Varenicline at a dose of 0.5 (but not 0.05)
mg kg1 day1 for 3 weeks signiﬁcantly progressed plaque forma-
tion in the aortic arch and whole aorta, in ApoE KO mice compared
with vehicle and low-dose (0.05 mg kg1 day1) varenicline groups
(Figs. 1 and 2). Plaques in the aortic arch and whole aorta formed
by varenicline treatment (0.5 mg kg1 day1 for 3 weeks) were
1.6- and 1.5-fold increased, respectively, compared with vehicle.
This higher dose of varenicline showing signiﬁcant and marked
aggravation in plaque formation was employed in the following
experiment.
3.2. Experiment 2
To determine the mechanism by which varenicline aggravates
atherosclerotic plaque formation, we examined the effect of MLA,
an a7 nAChR antagonist, on varenicline-induced aggravation ofAortic
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Fig. 3. Atherosclerotic plaques in the aorta of varenicline- and varenicline plus MLA-trea
the aortic root. (B) Pooled data of plaque area in the aortic root. Each bar indicates meaatherosclerotic plaque formation in ApoE KO mice. With combined
varenicline and MLA treatment, varenicline-induced aggravation of
atherosclerotic plaque formation in the aortic arch and whole aorta
of ApoE KO mice were not observed (Fig. 2). Moreover, atheroscle-
rotic plaque formation was markedly increased by 178% in the aor-
tic root of the varenicline group (Fig. 3). MLA also inhibited
varenicline-induced aggravated plaque formation in the aortic root
(Fig. 3). There were no signiﬁcant differences in body weight and
total plasma cholesterol levels between vehicle, varenicline, and
MLA plus varenicline groups (Table 1).4. Discussion
Patients with cardiovascular disease, even though receiving
drug therapy, are at high risk for the occurrence of cardiovascular
events. To decrease this risk, patients are strongly recommended to
stop smoking [1]. Varenicline is one of the most effective drugs for
smoking cessation [6–8]; however, when compared with a placebo,
an increased risk of cardiovascular events has been reported in
patients taking varenicline [10,11]. Therefore, in this study, we
determined if varenicline causes progression of plaque formation
in ApoE KO mice. Long-term varenicline treatment at a dose of
0.5 mg kg1 day1 progressed plaque formation in the aortic arch
and whole aorta of ApoE KO mice (Fig. 1), suggesting that vareni-
cline may increase the risk for occurrence of cardiovascular events.
Varenicline is an a4b2 nAChR partial agonist and an a7 nAChR
full agonist [5]. Varenicline efﬁcacy in smoking cessation is due to Root
nicline MLA+varenicline 
line MLA+ 
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ted ApoE KO mice. (A) Representative cross-sections of oil red O-stained plaques in
n ± S.D. ⁄P < 0.05 vs vehicle group, dP < 0.05 vs varenicline treatment group.
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mesolimbic dopaminergic system. Varenicline prevents nicotine
from binding to and moderately stimulates these receptors, leading
to inhibition of nicotine reinforcement during smoking and
reduced craving during smoking abstinence. Nevertheless, vareni-
cline efﬁcacy in a7 nAChR activation is 8-fold less potent than at
a4b2 nAChRs [5]. Considering that in the clinic long-term vareni-
cline treatment is ongoing for several months, it is highly likely
that a signiﬁcant effect of varenicline occurs because of activation
of a7 nAChR. The a7 nAChR is expressed on cells associated with
atherosclerotic plaque formation, including human vascular
smooth muscle cells, aortic endothelial cells, platelets, macro-
phages, and T and B lymphocytes. Among these human cell types,
the a4 subunit is expressed on vascular smooth muscle cells and B
lymphocytes, while the b2 subunit is expressed on aortic endothe-
lial cells and T lymphocytes [18–21]. Therefore, varenicline
appears to aggravate plaque formation by acting on a7 rather than
a4b2 nAChRs. This is likely associated with varenicline-induced
cardiovascular events, although further experiments are required
to clarify the target cell of varenicline-induced aggravation of pla-
que formation.
To determine if varenicline aggravates atherosclerosis forma-
tion via a7 nAChR, varenicline was administered to ApoE KO mice
in combination with MLA, an a7 nAChR antagonist. As shown in
Figs. 2 and 3, MLA inhibited varenicline-aggravated plaque forma-
tion in the aortic arch, whole aorta, and aortic root of ApoE KO
mice. These results strongly support the notion that varenicline
aggravates plaque formation through a7 nAChR, and thereby
causes adverse cardiovascular reactions. In addition, there are
reports suggesting that the a7 nAChR play a crucial role in the
mediation of nicotine-induced dendritic cell maturation, platelet
activation, and E-selectin expression in aortic endothelial cells
[21–23]; all phenomena involved in the progression of atheroscle-
rotic plaque formation. Furthermore, one case report found that
varenicline has a prothrombotic effect via brainstem a7 nAChR
[24]. This is similar to the effects of nicotine, because acute nico-
tine administration is capable of inducing thrombosis. These
results support our present ﬁndings that demonstrate a7 nAChR
involvement in adverse cardiovascular reactions of varenicline.
In conclusion, varenicline aggravates plaque formation by stim-
ulating a7 nAChR, and consequently may increase the risk for car-
diovascular events. The possibility that varenicline is involved in
adverse cardiovascular effects through a7 nAChR must be
considered.
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